Clinical trial / 2009
Oral curcumin reduced paraprotein load in half of patients with baseline paraprotein levels over 20 g/L and decreased a bone turnover marker in 27% of patients.
Twenty-six patients with monoclonal gammopathy of undefined significance (MGUS) were administered 4 grams/day of oral curcumin to examine its effects on plasma cells and osteoclasts. Among patients with a paraprotein level >20 g/L, 50% (5 of 10) experienced a 12% to 30% reduction in paraprotein levels during curcumin therapy. Additionally, 27% of patients on curcumin demonstrated a >25% decrease in the bone turnover marker urinary N-telopeptide of type I collagen.
- Study type
- Intervention trial
- Who was studied
- 26 patients with MGUS
- What was measured
- Paraprotein load, urinary N-telopeptide of type I collagen, and other markers
THE PAPER
The potential role of curcumin in patients with monoclonal gammopathy of undefined significance--its effect on paraproteinemia and the urinary N-telopeptide of type I collagen bone turnover marker.
Golombick T, Diamond TH, Badmaev V, Manoharan A, Ramakrishna R. Clin Cancer Res, 2009.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.